Over the past decade, targeting Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations has shifted from being considered an undruggable target to becoming a realistic therapeutic strategy with the development of KRASG12C inhibitors. This mutation replaces glycine with cysteine at codon 12, thereby reducing the GTP...
SJ2 is a promising lead for α‐amylase inhibition, which needs further optimization and biological validation, and future evaluation against α‐glucosidase and relevant in vivo models will be essential to determine the more general antidiabetic potential of this scaffold.
Sahil Jaidka, Ankush Kumar, Christopher Basumatary et al.· Chemistry and Biodiversity· 0 citations
Neolignans are potential natural product-derived anticancer leads; rational SAR-guided optimization, sophisticated delivery methods, and computational drug development may speed up their clinical translation.
Samarth Kumar, Ankush Kumar, Thakur Gurjeet Singh et al.· European journal of medicina...· 0 citations
The theoretical framework, rationalization, and therapeutic benefits of the MTAs, and the critical issues under the pharmacokinetics, toxicity, and clinical development are discussed, and the future outlook is on AI-based precision antiviral therapeutics.
Vrinda Gupta, Sahil Sharma, Vikrant Abbot et al.· Frontiers in Virology· 0 citations
Nanomedicine represents a promising approach for overcoming the limitations of conventional epilepsy therapy by enabling efficient brain-targeted drug delivery by enabling efficient brain targeting of antiepileptic drugs.
Abhishek Chauhan, Ankush Kumar, Ankit Awasthi et al.· The Journal of pharmacy and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
